Actively Recruiting
Resistant Potato Starch to Alleviate GWI
Led by VA Office of Research and Development · Updated on 2026-05-06
52
Participants Needed
1
Research Sites
177 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Gulf War Illness (GWI) affects an estimated 25-32% of the over 700,000 coalition troops deployed to the Persian Gulf as part of the First Gulf War. GWI causes a range of pain, fatigue, gastrointestinal, skin, neurologic, and respiratory symptoms. New treatments to reduce GWI-associated morbidity are critically needed. Research suggests a role for the gastrointestinal microbiome in mediating health, including through impacting metabolism and immunity. The disruption of this microbiome plays a role in multiple diseases, and preliminary data suggest that Veterans with GWI have altered gut microbiota. The investigators will evaluate the effectiveness of a dietary fiber prebiotic supplement intervention on improving the quality of life of Veterans with GWI.
CONDITIONS
Official Title
Resistant Potato Starch to Alleviate GWI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to provide informed written consent
- Willingness to comply with all study procedures and provide stool samples
- Meeting the modified Kansas Gulf War Illness case definition with gut symptoms
- Deployed to the Persian Gulf during Operations Desert Storm or Desert Shield
- Aged between 50 and 85 years old
You will not qualify if you...
- Known COVID-19 infection in the last 60 days or long COVID symptoms lasting more than 6 months
- Unable or unwilling to provide consent
- Alcohol abuse (more than 14 drinks per week for men, 7 drinks per week for women)
- Use of investigational drugs, biologics, or devices within 30 days before randomization
- Pregnant, lactating, or planning pregnancy during the study
- Diagnosed inflammatory bowel disease, Crohn's disease, or Celiac's disease
- Uncontrolled or untreated hypothyroidism
- Previous gastrointestinal surgery (colorectal surgery, gastric bypass, intestinal resection)
- Systemic antibiotics within 30 days
- Fecal microbiota transplant within 30 days
- Active difficulty swallowing (dysphagia)
- Allergies to any ingredients in MSPrebiotic
- Use of immunomodulatory medications within 30 days
- Any condition or medication that could affect gut response or study results as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
William S. Middleton Memorial Veterans Hospital, Madison, WI
Madison, Wisconsin, United States, 53705-2254
Actively Recruiting
Research Team
N
Nasia Safdar, MD PhD
CONTACT
J
Julie A Keating, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here